In TRA-2P Study, Adding Merck’s Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events
Drugs KILL, Plants CURE.
Drink Life In!®
~ Uncle Russ
Researchers today presented and published results from the TRA-2P (Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) TIMI 50 study of vorapaxar, Merck’s investigational anti-thrombotic medicine, in patients with a prior history of cardiovascular events or disease.